Background
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Brain Stimulation: Basic, Translational, and Clinical Research in NeuromodulationReferences
- Current approaches to the pharmacologic treatment of anxiety disorders.Psychopharmacol Bull. 2007; 40: 98-109
- The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective.J Clin Psychiatry. 2007; 68: 10-19
- Quality of life in the anxiety disorders: a meta-analytic review.Clin Psychol Rev. 2007; 27: 572-581
- An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone.Biol Psychol. 2007; 74: 185-199
- Vagus nerve stimulation: a new tool for brain research and therapy.Biol Psychiatry. 2000; 47: 287-295
- Vagus nerve stimulation: a research update.Neurology. 2002; 54: S56-S61
- Therapeutic mechanisms of vagus nerve stimulation.Neurology. 2002; 59: S15-S20
- Locus coeruleus lesions suppress the seizure attenuating effects of vagus nerve stimulation.Epilepsia. 1998; 39: 709-714
- Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus.Proc Natl Acad Sci U S A. 1995; 92: 8788-8792
- A novel long-latency response of locus coeruleus neurons to noxious stimuli: mediation by peripheral C-fibers.J Neurophysiol. 1994; 71: 1752-1761
- Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus.Brain Res Mol Brain Res. 1993; 18: 121-126
- Axonal sprouting of noradrenergic locus coeruleus neurons following repeated stress and antidepressant treatment.Prog Brain Res. 1991; 88: 587-598
- Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder.Br J Psychiatry. 1990; 157: 762-765
- Fluvoxamine as an antiobsessional agent.Psychopharmacol Bull. 1989; 25: 31-35
- Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures.Epilepsy Res. 1995; 20: 221-227
- A review of functional neuroimaging studies of vagus nerve stimulation (VNS).J Psychiatr Res. 2003; 37: 443-455
- Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI.Invest Radiol. 2001; 36: 470-479
- Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency/dose dependent effects.J Psychiatr Res. 2002; 36: 219-227
- Acute vagus nerve stimulation using different pulse widths produces varying brain effects.Biol Psychiatry. 2004; 55: 816-825
- Serial vagus nerve stimulation functional MRI (VNS/fMRI) in Treatment resistant depression.Neuropsychopharmacol. 2007; 32: 1-12
- Seizure suppression by systemic epinephrine is mediated by the vagus nerve.Epilepsy Res. 2000; 38: 171-175
- Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression.Epilepsia. 2001; 42: 586-589
- Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.Biol Psychiatry. 2000; 47: 276-286
- The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression.Neuropsychiatry Neuropsychol Behav Neurol. 2001; 14: 53-62
- Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.Neuropsychopharmacol. 2001; 25: 713-728
- Two-year outcome of vagus nerve stimulation (VNS) therapy for major depressive episodes.J Clin Psychiatry. 2005; 66: 1097-1104
- A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.Biol Psychiatry. 2005; 58: 364-373
- Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.Biol Psychiatry. 2005; 58: 347-354
- Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.Biol Psychiatry. 2005; 58: 355-363
- Efficacy of carbamazepine in manic-depressive illness: implications for underlying mechanisms.in: Post R.M. Ballenger J.C. Neurobiology of Mood Disorders. Williams and Wilkins, Baltimore1984: 777-816
- Prophylactic efficacy of carbamazepine in manic-depressive illness.Am J Psychiatry. 1983; 140: 1602-1604
- Anticonvulsants in psychiatric disease: when are they effective?.Drug Therapy. 1985; 15: 144-156
- The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.J Clin Psychopharmacol. 2007; 27: 263-272
- Vagus nerve stimulation for treatment of partial seizures: 1, a controlled study of effect on seizures.Epilepsia. 1994; 35: 616-626
- Vagus nerve stimulation for treatment of partial seizures: 2, long-term follow-up on first 67 patients exiting a controlled study.Epilepsia. 1994; 35: 637-643
- Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.Biol Psychiatry. 2000; 47: 276-286
- Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome.Neuropsychopharmacol. 2001; 25: 713-728
- The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.Psychol Med. 2004; 34: 73-82
- A rating scale for mania: reliability, validity and sensitivity.Br J Psychiatry. 1978; 133: 429-435
- The MOS 36-item short-form health survey (SF-36): I, conceptual framework and item selection.Med Care. 1992; 30: 473-483
- Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues.Neurosurg Clin N Am. 2003; 14: 199-212
- Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder.Neuropsychopharmacol. 2006; 31 ([erratum appears in Neuropsychopharmacol 2006 Nov;31(11):2394]): 2384-2393
- What is an emotion?.Mind. 1884; 9: 188-205
Article info
Publication history
Footnotes
This study was supported in part by grants from Cyberonics, Inc. Data were collected by Quintiles Transnational Corp. Statistical analyses were performed by Amara K. Jayewardene, MS, and John Allen, Jr., PhD, of Cyberonics, Inc., manufacturer of the VNS Therapy System and reviewed by the authors. Susan E. Siefert, ELS, CBC, also of Cyberonics, assisted with the development of the manuscript.
Dr. George has received research grants from Cyberonics, and is on the Cyberonics Depression and Mechanism of Action Scientific Advisory Boards.
Dr. Nahas has received research grants and speaking fees from Cyberonics.
Dr. Robert H. Howland has received research support from Aspect Medical Systems; Bristol-Myers Squibb; Cyberonics; Forest; Cederroth; National Institutes of Mental Health; National Center for Complementary and Alternative Medicine. He has received speaking fees from Wyeth; Bristol-Myers Squibb; AstraZeneca; Cyberonics.
Amara Jayewardene, MS, John Allen, Jr, PhD, and Susan E. Siefert, ELS, CBC, are employees of Cyberonics.
Dr. Allen and Ms Siefert own Cyberonics stock. Dr. Ninan is now an employee of Wyeth Pharmaceuticals.
Dr. Pollack is a paid adviser, consultant or speaker for AstraZeneca, Brain Cells Inc, Bristol Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Jazz Pharmaceuticals, Eli Lilly, Medavante, Neurocrine, Neurogen, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche, Laboratories, Sanofi, Sepracor, Solvay, Tikvah Therapeutics, Transcept Inc, UCB Pharma, and Wyeth. He has equity stake in Medavante and Mensante Corporation. He has received research grants from Bristol Myers Squibb, Cephalon, Cyberonics, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, NARSAD, NIDA NIMH, Pfizer, Sepracor, UCB Pharma, and Wyeth.
Although Cyberonics sponsored the trial, the authors were involved in initial study design, data collection, manuscript writing, and have had full access to the data.
Aspects of this trial have been previously reported in poster format at:
George MS, et al: Vagus nerve stimulation (VNS) shows potential therapeutic benefit for severe anxiety disorders in an initial open trial. 41st American College of Neuropsychopharmacology Annual Meeting. December 2002.
Ward H, et al: Treatment-refractory obsessive-compulsive disorder: potential benefit of VNS therapy. 23rd Annual Conference of the Anxiety Disorders Association of America. March 2003.
George MS, et al: Open trial of VNS therapy in severe anxiety disorder. 156th American Psychiatric Association Annual Meeting. May 17-22, 2003, San Francisco, California.
